Parker Institute for Cancer Immunotherapy

Parker Institute for Cancer Immunotherapy

The Parker Institute for Cancer Immunotherapy (PICI) operates as a networked research institute rather than a passive grantmaker. It was established to coordinate the efforts of top cancer centers, building a collaborative framework that allows scientists and clinicians to share data, conduct joint clinical trials, and speed the development of immunotherapies. PICI structures its work around multi-center research projects rather than standalone academic awards. Its network partners include leading institutions across the United States, with its integrated model designed to enable the rapid translation of preclinical findings into human studies. The institute does not treat patients directly but facilitates clinical trials at its member centers, focusing exclusively on immune-based approaches to cancer. The organization maintains a distributed footprint with multiple hubs in North America and Europe to support its research collaborations. While PICI operates primarily through its network, it has expanded its leadership team with specialized hires. PICI appointed Bolyn Hubby as Chief of Staff and Aimee Johnson as Chief Marketing Officer, signaling deliberate investment in operational capacity beyond its scientific core. PICI’s structural distinction lies in its insistence on direct research participation. Unlike conventional philanthropies that fund proposals at arm’s length, the institute embeds itself in the scientific process by uniting competing research centers under a single, collaborative umbrella — a model designed to collapse the time between hypothesis and treatment.